Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety and Tolerability of Pradigastat in Patients With Functional Constipation

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety and Tolerability of Pradigastat in Patients With Functional Constipation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pradigastat (Primary)
  • Indications Constipation
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Anji Pharma

Most Recent Events

  • 07 Jun 2022 Status changed from active, no longer recruiting to completed.
  • 18 May 2022 According to an Anji Pharma media release, the trial is being conducted in five clinical sites in the U.S. and 20 clinical sites in China. The company plans to report topline data from this study in the second half of 2022.
  • 18 May 2022 Status changed from recruiting to active, no longer recruiting, according to an Anji Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top